top of page

Pipeline
Who We Are
NanO₂
Glioblastoma
Publications
News
Contact
More

Use tab to navigate through the menu items.

The latest from NuvOx

All Posts
News
Events
Publications
Hemorrhagic Shock
Mechanism Of Action
Myocardial Infarction
Oncology
Pharmacokinetics
Stroke
Traumatic Brain Injury
Other

Search

NuvOx Pharma Announces Issuance of a New Patent

Award of this patent broadens NuvOx’s extensive patent portfolio of perfluorocarbon-based therapeutic formulations to reverse hypoxia.

May 19, 2022

NuvOx Appoints Dr. Robert King to SAB

Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...

May 9, 2022

NuvOx Technology Featured in Prominent Peer Review Journal

Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...

May 9, 2022

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...

May 9, 2022

NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program

On February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...

Mar 4, 2022

NuvOx Therapeutics

1635 E 18th Street

Tucson, Arizona 85719

Terms & Conditions

© 2025 NuvOx Therapeutics

Pipeline
Who We Are
NanO₂
Glioblastoma

Publications
News
Contact
Careers

bottom of page